查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179902

2023-2030全球鎮痛藥市場

Global Pain Relief Medication Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

疼痛是由於組織損傷或疾病而產生的一種不舒服的感覺。 多種情況都會引發痛苦，包括腹部潰瘍、硬化、骨關節炎、慢性關節炎、糖尿病性神經病變和癌症。 感覺性疼痛可分為長期慢性疼痛和持續數月、數週或數天的短期急性疼痛。 另一方面，慢性疼痛會持續多年。

市場動態

在預測期內，為改善患者生活質量而對止痛藥的需求不斷增加，正在推動全球止痛藥市場的增長。

對止痛藥不斷增長的需求正在推動全球市場的增長。

鎮痛劑可緩解術後疼痛、嚴重身體損傷或癌症疼痛等情況下的極度疼痛。 它也用於其他長期疼痛。 術後疼痛、身體創傷以及慢性非傳染性疾病（如關節炎和癌症）的增加正在創造對止痛藥的需求。 例如，據世界衛生組織稱，每年有超過數百萬人遭受非致命傷害，導致住院、全科醫生護理、急診室和急症護理醫院就診，而且通常是暫時性傷害。或遭受永久性傷害失能。 此外，國際癌症研究機構（WHO）估計，2020 年全球約有 19,292,789 例不同類型癌症的新病例。 同樣，根據全球類風濕性關節炎網絡，到 2021 年將有大約 3.5 億人患有關節炎。 此外，美國國立衛生研究院指出，超過 75% 的接受手術的患者會經歷急性術後疼痛，其嚴重程度可能為中度至重度。

此外，全球手術數量的增加也在擴大全球鎮痛劑市場。 例如，根據歐洲核心健康指標 (ECHI)，白內障手術和剖腹產是歐盟醫院最常進行的兩種手術/程序。 2020 年，歐盟成員國共進行了 366 萬次白內障手術。 與此同時，2020 年歐盟至少進行了 112 萬例剖腹產手術。

其他止痛療法的可用性和採用仍然是全球市場增長的主要障礙。

但是，其他使用低壓電流來治療疼痛的鎮痛療法，例如經皮神經電刺激 (TENS) 療法，已經可用並被引入。 此外，2021 年 1 月，波士頓科學公司將推出 WaveWriter Alpha，這是一種脊髓刺激器 (SCS) 系統組合，包含用於緩解個性化疼痛的治療選項。

COVID-19 影響分析

COVID-19 大流行對全球止痛藥市場產生了重大影響。 2019 年冠狀病毒病 (COVID-19) 流行期間的慢性疼痛管理一直具有挑戰性，尤其是越來越多的證據表明 COVID-19 感染與肌痛、參照痛和廣泛痛覺過敏有關。。 非阿片類鎮痛藥，單獨使用或與非甾體抗炎藥 (NSAIDs) 聯合使用，作為多模式鎮痛的一部分來控制輕度至中度疼痛，可能與發燒、頭痛、急性或慢性疼痛有關。它被安全地用於緩解COVID-19 的症狀，如疼痛，導致對止痛藥的需求增加，這對市場增長產生了積極影響。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 對止痛藥的需求不斷增加
      • 老年人口增加
    • 約束因素
      • 其他替代方案的可用性
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第7章給藥途徑

  • 口服劑
  • 注射
  • 外部代理

第 8 章按類型

  • 急性期
  • 慢性期

第 9 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準

第12章公司簡介

  • 梯瓦製藥工業有限公司
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Bayer AG
  • Sanofi S.A.
  • GlaxoSmithKline plc.
  • Bristo-Meyers Squibb and Company
  • Mylan N.V.
  • Merck & Co.
  • Cardinal Health Inc.

第13章 DataM

簡介目錄
Product Code: DMPH6131

Market Overview

The global pain relief medication size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Pain is a troubling sensation developed because of tissue injury or disease. Various conditions can induce distress, like abdominal ulcers, sclerosis, osteoarthritis, chronic arthritis, diabetic neuropathy, and cancer. Based on the duration of pain, sensation pain is of two types chronic, lasting for the long term, and acute pain for the short term, which can last for months, weeks, or days. In contrast, chronic pain lasts for years.

Market Dynamics

The rising need for pain-relieving medication to increase the patient quality of life is boosting the global pain-relief medication market growth during the forecast period.

The growing demand for pain-relieving medication is fueling the market growth globally.

Pain Relief Medications alleviate extreme pain in conditions such as post-surgery pain, a serious physical injury, or pain from cancer. They are also used for other types of long-standing pain. The growing number of postoperative pains, physical traumas and chronic non-communicable diseases such as arthritis and cancer are creating the demand for Pain Relief Medication. For instance, according to the WHO, more than millions suffer non-fatal injuries each year, which lead to hospitalizations or treatment by general practitioners or emergency department and acute care visits and often result in temporary or permanent disability. Also, the International Agency for Research on Cancer WHO assessed there were about 19292789 new cases of different types of cancer globally in 2020. Similarly, according to the Global Rheumatoid Arthritis Network, approximately 350 million people lived with arthritis in 2021. Additionally, the NIH states that over 75% of the patients who have undergone surgery experience acute postoperative pain, which might be medium to high in severity.

Furthermore, the increasing number of surgeries performed globally also expands the global pain relief medication market. For instance, according to the European core health indicators (ECHI), the two most common surgical operations and procedures performed in EU hospitals were cataract surgery and cesarean sections. Cataract surgery was conducted 3.66 million times in 2020 across the EU Member States. At the same time, the cesarean section procedure was performed at least 1.12 million times in the EU in 2020.

The availability and introduction of other pain-relieving treatments is a major hurdle in the market's global growth.

However, the availability and introduction of other pain relieving treatments, such as Transcutaneous Electrical Nerve Stimulation (TENS) therapy, involves using low-voltage electric currents to treat pain. Furthermore, in January 2021, Boston Scientific Corporation introduced the WaveWriter Alpha, a portfolio of Spinal Cord Stimulator (SCS) systems that incorporate treatment choices for personalized pain relief.

COVID-19 Impact Analysis

The COVID-19 pandemic has greatly impacted the global pain relief medication market. Chronic pain management during the coronavirus disease 2019 (COVID-19) pandemic was difficult, particularly with rising proof that COVID-19 infection is associated with myalgias, referred pain, and widespread hyperalgesia. Non-Opioid Analgesic medication used alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDs) in addressing mild-to-moderate pain as part of multimodal analgesia, also be utilized safely to relieve symptoms of COVID-19, like fever, headache, and acute or chronic pain, which led to increased demand for pain relief medication and positively impacted the market growth.

Segment Analysis

The chronic pain type is predicted to hold a large share of the global pain relief medication market during the forecast period (2022-2029).

The chronic pain type is expected to hold most of the market share during the forecasted period. According to the Johns Hopkins Hospital, Chronic pain is long-standing pain that lasts beyond the normal healing period or surfaces along with a chronic health condition, like arthritis, Cancer pain, migraines, cluster headaches and others. Chronic pain may be "appearing" and "disappearing" or continuous. The U.S. spends $3.5 trillion annually on health care, with 90% of that going to chronic conditions, including chronic pain. Moreover, according to an article by The Lancet, Chronic pain exerts an immense individual and financial hindrance, impacting over 30% of individuals worldwide. Also, according to the NIH, Chronic pain is favorably dominant among geriatric adults, associated with substantial suffering, disability, social solitariness, and higher expenditures and burden to health care systems. Thus, the growing geriatric population is contributing to the growth of the chronic pain segment. For example, according to WHO, the geriatric population accounted for 1 billion in 2020 and is predicted to reach 1.4 billion by 2030. Thus the data mentioned above indicate that the chronic pain type will dominate the global pain relief medication market

Geographical Analysis

North America oppresses the global pain relief medication market throughout the forecast period (2022-2029).

Owing to the high number of chronic disease cases and the presence of key market players, the North American pain relief medication market is assessed to grow at a high CAGR in the forecast period (2022-2029). Such as, according to the American cancer society estimations, in 2022, about 1.9 million new cancer cases will be analyzed, and around 609,360 cancer-caused deaths in the United States. Likewise, CDC anticipated that approximately 78 million U.S. adults will live with doctor-diagnosed arthritis in 2040, increasing the demand for the Pain Relief Medication analgesic. Similarly, the major key players holding a larger share of the market are U.S. based, such as Johnson & Johnson, Pfizer Inc., Purdue Pharma, Endo International, Mylan, Impax Laboratories and Indivior, contributing to the dominance of North America over the global Pain Relief Medication market. Therefore from the data mentioned above, it is anticipated that North America will hold most of the global pain relief medication market throughout the forecasted period (2022-2029).

Competitive Landscape

The pain relief medication market is moderately competitive since there is a growing demand for pain relief medication and local and global key players. Some key players are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristo-Meyers Squibb and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co., and Cardinal Health Inc. These key players hold the market through acquisition, product launches, and collaborations. For instance, in July 2021, Venus Remedies Limited launched a consumer healthcare division that will offer various products for pain management.

Teva Pharmaceutical Industries Ltd.

Overview

Teva Pharmaceuticals was founded in 1901 in Jerusalem. It is today among the top 15 pharmaceutical companies worldwide. Teva has over 3600 medicines in its product portfolio, with 37,000 employees working globally and 53 production sites globally.

Product Portfolio:

Teva Pharmaceutical's product portfolio of pain relief medication has: Hydromorphone comes under the family of drugs known as opioid painkillers. It is employed to treat moderate-to-severe pain, such as pain after surgery.

The global pain relief medication market report would provide access to approximately 40 + market data tables, 45 + figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Demand for Pain Relief Medication
      • 4.1.1.2. Growing Geriatric Population
    • 4.1.2. Restraints
      • 4.1.2.1. Availability of Other Options
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration
  • 7.2. Oral
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Injectable
  • 7.4. Topical

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Acute
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Chronic

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacy
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Teva Pharmaceutical Industries Ltd.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Pfizer Inc.
  • 12.3. Johnson & Johnson Services Inc.
  • 12.4. Bayer AG
  • 12.5. Sanofi S.A.
  • 12.6. GlaxoSmithKline plc.
  • 12.7. Bristo-Meyers Squibb and Company
  • 12.8. Mylan N.V.
  • 12.9. Merck & Co.
  • 12.10. Cardinal Health Inc.

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us